Regeneron Pharmaceuticals
REGN
#331
Rank
โ‚ฌ62.90 B
Marketcap
600,03ย โ‚ฌ
Share price
-1.32%
Change (1 day)
17.41%
Change (1 year)

EPS for Regeneron Pharmaceuticals (REGN)

EPS in 2026 (TTM): 36,27ย โ‚ฌ

According to Regeneron Pharmaceuticals's latest financial reports the company's current EPS (TTM) is 36,18ย โ‚ฌ. In 2025 the company made an earnings per share (EPS) of 36,68ย โ‚ฌ an increase over its 2024 EPS that were of 34,77ย โ‚ฌ.

EPS history for Regeneron Pharmaceuticals from 2010 to 2026

Annual EPS

Year EPS Change
2026 (TTM)36,27ย โ‚ฌ-1.12%
202536,68ย โ‚ฌ5.48%
202434,77ย โ‚ฌ10.34%
202331,51ย โ‚ฌ-8.56%
202234,47ย โ‚ฌ-47%
202165,03ย โ‚ฌ133.36%
202027,87ย โ‚ฌ69.13%
201916,48ย โ‚ฌ-14.44%
201819,26ย โ‚ฌ100.71%
20179,59ย โ‚ฌ31.78%
20167,28ย โ‚ฌ38.96%
20155,24ย โ‚ฌ72.55%
20143,04ย โ‚ฌ-17.55%
20133,68ย โ‚ฌ-44.98%
20126,69ย โ‚ฌ
2010-1,08ย โ‚ฌ

EPS for similar companies or competitors

Company EPS EPS differencediff. Country
Johnson & Johnson
JNJ
7,43ย โ‚ฌ-79.46%๐Ÿ‡บ๐Ÿ‡ธ USA
Novartis
NVS
5,97ย โ‚ฌ-83.49%๐Ÿ‡จ๐Ÿ‡ญ Switzerland
Amgen
AMGN
12,32ย โ‚ฌ-65.95%๐Ÿ‡บ๐Ÿ‡ธ USA
Sanofi
SNY
2,18ย โ‚ฌ-93.98%๐Ÿ‡ซ๐Ÿ‡ท France
Biogen
BIIB
7,95ย โ‚ฌ-78.02%๐Ÿ‡บ๐Ÿ‡ธ USA
Alnylam Pharmaceuticals
ALNY
3,22ย โ‚ฌ-91.09%๐Ÿ‡บ๐Ÿ‡ธ USA